Liraglutide + Placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Obesity, Visceral

Conditions

Obesity, Visceral, Cardiovascular Diseases, Fat Disorder

Trial Timeline

Jan 1, 2017 → Oct 13, 2020

NCT ID

NCT03038620

About Liraglutide + Placebo

Liraglutide + Placebo is a approved stage product being developed by Novo Nordisk for Obesity, Visceral. The current trial status is completed. This product is registered under clinical trial identifier NCT03038620. Target conditions include Obesity, Visceral, Cardiovascular Diseases, Fat Disorder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04775082	Phase 3	Active	Mar 4, 2021	Jan 15, 2027	Obesity
NCT03712098	Phase 2	Completed	Nov 29, 2018	May 25, 2022	Smoking Cessation
NCT03523273	Phase 2	Completed	Nov 29, 2017	Aug 31, 2021	Obesity
NCT02953665	Phase 2	Completed	Apr 3, 2017	Aug 3, 2022	Parkinson Disease
NCT02964247	Phase 3	Completed	Mar 3, 2017	May 8, 2018	Diabetes
NCT02963935	Phase 3	Completed	Feb 6, 2017	Jun 19, 2018	Metabolism and Nutrition Disorder
NCT03038620	Approved	Completed	Jan 1, 2017	Oct 13, 2020	Obesity, Visceral
NCT02889510	Phase 3	Completed	Oct 4, 2016	Dec 16, 2019	Type 2 Diabetes
NCT02918279	Phase 3	Completed	Sep 29, 2016	Aug 8, 2019	Metabolism and Nutrition Disorder
NCT02717858	Phase 1	Completed	Mar 16, 2016	Feb 27, 2017	Metabolism and Nutrition Disorder
NCT02696148	Phase 1	Completed	Mar 14, 2016	Apr 13, 2017	Metabolism and Nutrition Disorder
NCT02655770	Approved	Completed	Feb 1, 2016	Dec 1, 2019	Diabetes Mellitus Type 2
NCT02647944	Phase 2	Completed	Dec 18, 2015	Dec 30, 2016	Obesity
NCT02527200	Phase 3	Completed	Nov 9, 2015	Nov 19, 2020	Metabolism and Nutrition Disorder
NCT02473809	Approved	Completed	Aug 1, 2015	Oct 1, 2017	Diabetes Complications
NCT02545738	Approved	Completed	Apr 1, 2015	May 1, 2016	Diabetic Kidney Disease
NCT02284230	Phase 2	Withdrawn	Dec 1, 2014	Aug 1, 2015	Kidney Failure, Chronic
NCT01789086	Phase 1	Completed	Feb 1, 2013	May 1, 2014	Metabolism and Nutrition Disorder
NCT01755572	Approved	Completed	Jan 1, 2013	Mar 1, 2014	Type 2 Diabetes
NCT02113332	Phase 2	Completed	Jan 1, 2013	Aug 1, 2014	Type 2 Diabetes Mellitus

Competing Products

20 competing products in Obesity, Visceral

See all competitors

Product	Company	Stage	Hype Score
MK0493	Merck	Phase 2	52
MK0557	Merck	Phase 3	77
AMG 786	Amgen	Phase 1	32
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo	Eli Lilly	Phase 2	52
Tirzepatide	Eli Lilly	Phase 2	52
exenatide + Placebo	Eli Lilly	Approved	85
Brenipatide	Eli Lilly	Phase 1	33
Orforglipron + Placebo	Eli Lilly	Phase 3	77
TERN-601	Terns Pharmaceuticals	Phase 2	49
MBX 4291 + Placebo	MBX Biosciences	Phase 1	28
PG-102	Rani Therapeutics	Phase 1	25
Orforglipron + Placebo	Eli Lilly	Phase 1	33
Tirzepatide + Placebo	Eli Lilly	Phase 3	77
Eloralintide + Placebo	Eli Lilly	Phase 1	33
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo	Eli Lilly	Phase 2	52
LY3437943 + Midazolam + Warfarin + Caffeine	Eli Lilly	Phase 1	33
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Skye Bioscience	Phase 2	44
Tirzepatide	Eli Lilly	Approved	85
Adenosine + Regadenoson	Astellas Pharma	Pre-clinical	23
Micafungin + Micafungin	Astellas Pharma	Approved	85

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved